The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Approaching tumour therapy beyond platinum drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
International Journal of Oncology
(2026) · International Journal of Oncology · doi:10.3892/ijo · Cited by 2,331
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
Organometallic Anticancer Compounds
Gasser, G., Ott, I., & Metzler-Nolte, N. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm100020w · Cited by 1,624
Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., & Keppler, B. K. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.02.013 · Cited by 956
Antitumour metal compounds: more than theme and variations
Jakupec, M. A., Galanski, M. S., Arion, V. B., Hartinger, C. G., & Keppler, B. K. (2008) · Dalton Transactions · doi:10.1039/b712656p · Cited by 850
Rademaker-Lakhai, J. M., van den Bongard, D., Pluim, D., Beijnen, J. H., & Schellens, J. H. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0746 · Cited by 833
Self-citationHartinger, C. G., Jakupec, M. A., Zorbas‐Seifried, S., Groessl, M., Egger, A., Berger, W., Zorbas, H., Dyson, P. J., & Keppler, B. K. (2008) · Chemistry & Biodiversity · doi:10.1002/cbdv.200890195 · Cited by 830
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Scolaro, C., Bergamo, A., Brescacín, L., Delfino, R., Cocchietto, M., Laurenczy, G., Geldbach, T. J., Sava, G., & Dyson, P. J. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050015d · Cited by 784
Self-citationGalanski, M. S., Jakupec, M. A., & Keppler, B. K. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637626 · Cited by 721
Ruthenium metallopharmaceuticals
Clarke, M. J. (2003) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(02)00312-0 · Cited by 687
Non Platinum Metal Complexes as Anti‐cancer Drugs
Ott, I., & Gust, R. (2007) · Archiv der Pharmazie · doi:10.1002/ardp.200600151 · Cited by 609
Recent developments in ruthenium anticancer drugs
Levina, A., Mitra, A., & Lay, P. A. (2009) · Metallomics · doi:10.1039/b904071d · Cited by 592
Aird, R. E., Cummings, J., Ritchie, A. A., Muir, M., Morris, R. E., Chen, H., Sadler, P. J., & Jodrell, D. I. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600290 · Cited by 582
Allardyce, C. S., Dyson, P. J., Ellis, D. J., & Heath, S. L. (2001) · Chemical Communications · doi:10.1039/b104021a · Cited by 495
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Ruthenium Antimetastatic Agents
Alessio, E., Mestroni, G., Bergamo, A., & Sava, G. (2004) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026043387421 · Cited by 479
Self-citationFuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432
DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity
Brabec, V., & Nováková, O. (2006) · Drug Resistance Updates · doi:10.1016/j.drup.2006.05.002 · Cited by 384
Exploring biologically relevant chemical space with metal complexes
Meggers, E. (2007) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2007.05.013 · Cited by 274
Ruthenium Half‐Sandwich Complexes Bound to Protein Kinase Pim‐1
Debreczeni, J. É., Bullock, A. N., Atilla, G. E., Williams, D. S., Bregman, H., Knapp, S., & Meggers, E. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200503468 · Cited by 234
Smalley, K. S. M., Contractor, R., Haass, N. K., Kulp, A. N., Atilla-Gokcumen, G. E., Williams, D. S., Bregman, H., Flaherty, K. T., Soengas, M. S., Meggers, E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1538 · Cited by 230
Muggia, F. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.09.034 · Cited by 221
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4408 · Cited by 208
Self-citationModulation of the metastatic progression of breast cancer with an organometallic ruthenium compound
Bergamo (1992) · International Journal of Oncology · doi:10.3892/ijo_00000119 · Cited by 202
Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex
Sava, G., Capozzi, I., Clerici, K., Gagliardi, G., Alessio, E., & Mestroni, G. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006521715400 · Cited by 183
Self-citationBergamo, A., Gagliardi, R., Scarcia, V., Furlani, A., Alessio, E., Mestroni, G., & Sava, G. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38169-8 · Cited by 160
Self-citationGaiddon, C., Jeannequin, P., Bischoff, P., Pfeffer, M., Sirlin, C., & Loeffler, J. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089342 · Cited by 142
Self-citationInhibition of endothelial cell functions and of angiogenesis by the metastasis inhibitor NAMI-A
Vacca, A., Bruno, M., Boccarelli, A., Coluccia, M., Ribatti, D., Bergamo, A., Garbisa, S., Sartor, L., & Sava, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600176 · Cited by 140
Self-citationNováková, O., Kašpárková, J., Bursová, V., Hofr, C., Vojtíšková, M., Chen, H., Sadler, P. J., & Brabec, V. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2004.11.008 · Cited by 136
An Organometallic Inhibitor for Glycogen Synthase Kinase 3
Bregman, H. S., Williams, D. S., Atilla, G. E., Carroll, P. J., & Meggers, E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja046049c · Cited by 127
Kapitza, S. B., Jakupec, M. A., Uhl, M., Keppler, B. K., & Marian, B. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.002 · Cited by 119
Atilla‐Gokcumen, G. E., Williams, D. S., Bregman, H. S., Pagano, N., & Meggers, E. (2006) · ChemBioChem · doi:10.1002/cbic.200600117 · Cited by 118
Bonetti, A. V., Leone, R., Muggia, F. M., & Howell, S. B. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-459-3 · Cited by 112
Novel Concepts in the Development of Platinum Antitumor Drugs
Fuertes, M. A., Castilla, J., Alonso, C., & Perez, J. (2002) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011023353958 · Cited by 105
Gava, B., Zorzet, S., Spessotto, P., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.095141 · Cited by 94
Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers
Morbidelli, L., Donnini, S., Filippi, S., Luigi Messori, A., Piccioli, F., Orioli, P., Sava, G., & Ziche, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600906 · Cited by 92
Self-citationSava, G., Frausin, F., Cocchietto, M., Vita, F., Podda, E., Spessotto, P., Furlani, A., Scarcia, V., & Zabucchi, G. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.034 · Cited by 91
Self-citationHayward, R. L., Schornagel, Q. C., Tente, R., Macpherson, J. S., Aird, R. E., Guichard, S. M., Habtemariam, A., Sadler, P. J., & Jodrell, D. I. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0932-9 · Cited by 79
Pintus, G., Tadolini, B., Posadino, A. M., Sanna, B., Debidda, M., Bennardini, F., Sava, G., & Ventura, C. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2002.03307.x · Cited by 71
Self-citationMusgrove, E. A., Rugg, C. A., Taylor, I. W., & Hedley, D. W. (1984) · Journal of Cellular Physiology · doi:10.1002/jcp.1041180103 · Cited by 60
Amin, A., & Buratovich, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709790361566 · Cited by 47
Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A.
Magnarin, M., Bergamo, A., Carotenuto, M. E., Zorzet, S., & Sava, G. (2000) · PubMed · Cited by 39
Self-citationNováková, O., Malina, J., Suchánková, T., Kašpárková, J., Bugarcic, T., Sadler, P. J., & Brabec, V. (2010) · Chemistry - A European Journal · doi:10.1002/chem.200903078 · Cited by 25
New pharmacological strategies against metastatic spread
Perret, G. Y., & Crépin, M. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00614.x · Cited by 24
Casarsa, C., Mischis, M. T., & Sava, G. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.04.017 · Cited by 21
Self-citation
Cited by
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Trondl, R., Heffeter, P., Kowol, C. R., Jakupec, M. A., Berger, W., & Keppler, B. K. (2014) · Chem. Sci. · doi:10.1039/c3sc53243g · Cited by 675
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Combination of Ru(ii) complexes and light: new frontiers in cancer therapy
Mari, C., Pierroz, V., Ferrari, S., & Gasser, G. (2015) · Chemical Science · doi:10.1039/c4sc03759f · Cited by 570
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Thota, S., Rodrigues, D. A., Crans, D. C., & Barreiro, E. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01689 · Cited by 476
Metadata
- Authors
- Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G.
- Venue
- Journal of Inorganic Biochemistry
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 106
- Issue
- 1
- Pages
- 90-99
- ISSN
- 0162-0134 (ISSN-L)
- OpenAlex
- W127176811
- Cited by
- 514
- References
- 48
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.